Delricht LLC

1. Moderna TX, Inc. $47,594,783 14,648 payments
2. Eli Lilly and Company $2,156,627 42 payments
3. AbbVie, Inc. $1,816,568 192 payments
4. Pfizer Inc. $1,131,110 133 payments
5. Genzyme Corporation $956,491 162 payments
6. GlaxoSmithKline, LLC. $616,949 48 payments
7. Corium, Inc. $531,445 30 payments
8. Sanofi Pasteur Inc. $495,624 84 payments
9. Alnylam Pharmaceuticals Inc. $479,368 324 payments
10. Lexicon Pharmaceuticals, Inc. $387,855 33 payments

1. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $18,693,292 10,756 payments
2. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $6,896,341 144 payments
3. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $5,751,185 70 payments
4. A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $4,958,586 251 payments
5. A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age $2,942,796 181 payments
6. A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults $2,450,081 127 payments
7. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $1,941,049 2,145 payments
8. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $1,400,885 51 payments
9. A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older $1,129,626 69 payments
10. A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine $1,084,301 7 payments

1. Patient care $283,651 17 payments
2. Professional salary support $132,960 107 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.